

# Omeprazole + amoxicillin + rifabutin (TALICIA) Criteria for Use November 2024

VA Pharmacy Benefits Management Services and National Formulary Committee

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

See the VA National Formulary Committee Monograph on this drug at the [PBM INTRAnet](#) site for further information.

## Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive TALICIA.

- Concomitant rilpivirine, voriconazole or other serious drug-drug interactions that cannot be managed (e.g. other azoles, rifampin, some HIV protease inhibitors, high-dose methotrexate).
- Pregnancy
- History of severe hypersensitivity to penicillins, proton pump inhibitors or rifamycins
- Inability to swallow capsules whole

## Inclusion Criteria

All of the following criteria must be met.

- Documented H.pylori by laboratory test or pathology
- Failure to at least one course of bismuth quadruple therapy or vonoprazan dual therapy or contraindication to BOTH